ÉPALINGES, Switzerland, March 5, 2025 /PRNewswire-PRWeb/ Volv Global expands office footprint to more than double its office space for
On the occasion of international Rare Disease Day 2025, we are beyond thrilled to host the voice of patient advocate
Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys
This article is also available in French and originally published 24 Heures. Read the original article Based in Épalinges, the small
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults
Volv, supported by Sanofi, and working with Optimum Patient Care, and collaborating with a specialist Consultant Clinician, is performing research
By Volv Global SA and WODC EU contributors Executive Summary For decades, the pharmaceutical industry has faced the same
By Christopher Rudolf, Volv Global Rare disease patients and the journey to diagnosis, treatment, and support For patients with rare
By Christopher Rudolf, Volv Global Rare disease patients and the journey to diagnosis, treatment, and support For patients with rare
By Christopher Rudolf, Volv Global Introduction Rare Disease Day highlights the voices, stories, and experiences of millions of people living
In this early collaboration with Alnylam Pharmaceuticals and the PHARMO Institute for Drug Outcomes Research, Volv Global applied a novel
